Drug Profile
Fosciclopirox - CicloMed
Alternative Names: Ciclopirox phosphoryloxymethyl ester; Ciclopirox prodrug - CicloMed; CPX - CicloMed; CPX-POMLatest Information Update: 20 Dec 2023
Price :
$50
*
At a glance
- Originator University of Kansas
- Developer CicloMed; Notable Labs; University of Kansas
- Class Antifungals; Antineoplastics; Cyclohexanes; Phosphates; Pyridones; Small molecules
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bladder cancer
- Phase I/II Acute myeloid leukaemia
- No development reported Solid tumours
Most Recent Events
- 18 Dec 2023 Efficacy and adverse event data from a Phase I/II trial in Acute myeloid leukaemia released by Notable Labs
- 30 Jun 2023 CicloMed completes a phase II trial of Fosciclopirox for Bladder cancer (First-line therapy, Newly diagnosed, Recurrent) in USA (IV) (NCT04525131)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)